共 39 条
- [21] Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2019, 42 (06) : 841 - 852
- [22] Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial CardioVascular and Interventional Radiology, 2019, 42 : 841 - 852
- [27] The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial Journal of Patient-Reported Outcomes, 4
- [29] Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases Annals of Surgical Oncology, 2016, 23 : 1309 - 1319